Multicenter, open-label, single-arm study to evaluate long term safety, tolerability, and effectiveness of 10mg/kg BID olesoxime in patients with Spinal Muscular Atrophy

Trial Profile

Multicenter, open-label, single-arm study to evaluate long term safety, tolerability, and effectiveness of 10mg/kg BID olesoxime in patients with Spinal Muscular Atrophy

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs Olesoxime (Primary)
  • Indications Spinal muscular atrophy
  • Focus Adverse reactions
  • Acronyms OLEOS
  • Sponsors Roche
  • Most Recent Events

    • 07 Nov 2017 Planned End Date changed from 23 Apr 2021 to 8 May 2021.
    • 07 Nov 2017 Planned primary completion date changed from 23 Apr 2021 to 8 May 2021.
    • 03 May 2017 Planned End Date changed from 1 Dec 2020 to 23 Apr 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top